Guided by a multidisciplinary scientific committee comprised of clinical and research experts I-O Optimise…
- Yields real-world insights that support a broad range of healthcare stakeholders in their efforts to transform patient care in non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma
- Works towards the collective goal of improving patient outcomes in lung cancer.
I-O Optimise aims to deliver valuable insights that may help:
- Oncologists and other healthcare professionals to select appropriate therapies based on informed decisions
- Patients to be better informed about treatment choices and ultimately to achieve better outcomes
- Researchers to understand what additional information should be gathered when conducting clinical trials and what complementary evidence is lacking
- Payers and regulators to assess the value of innovative therapies.
The delivery of insights began in 2017, with regular updates over the long term as the treatment landscape evolves further. Over time, it should be possible to compare different populations and healthcare systems.
*I-O Optimise is generating data for non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma.
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol‑Myers Squibb Company.
Home Corporate Website Contact
Sitemap Privacy Policy
Legal Notice
